Devonian Health Group Inc. (CVE:GSD – Get Free Report) shares were up 10.4% on Wednesday . The company traded as high as C$11.15 and last traded at C$11.15. 2,138 shares were traded during trading, an increase of 79% from the average daily volume of 1,194 shares. The stock had previously closed at C$10.10.
Devonian Health Group Price Performance
The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The company has a market cap of C$31.15 million, a P/E ratio of -4.98 and a beta of 0.42. The firm’s fifty day moving average is C$8.77 and its two-hundred day moving average is C$10.69.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
